Printer Friendly

Disease activity and related variables in patients with psoriatic arthritis.

Psoriatic arthritis (PsA) is an inflammatory disease which accompanies psoriasis which is characterized by bone proliferation, osteolysis, and involvement of the enthesis regions. (1) Moll and Wright (2) described PsA as being milder than RA, but approximately 20% of patients with this disease develop destructive arthritis that causes disability and high mortality. Thus, PsA is not considered to be a mild disease, and the aim of treatment is remission. Until recently, there has not been much interest in assessment and outcome measurement with regard to PsA, (3) but with significant improvements in treatment, more attention is now being given to outcome measurements. For example, determining the symptoms and signs of PsA in the peripheral joints and skin, the quality of life (QoL), fatigue, and radiological damage is now deemed necessary. Most of these indices included in this study were not developed to assess PsA. Instead, they are commonly used for rheumatoid arthritis (RA), ankylosing spondylitis (AS), and psoriasis. However, several other indices have been especially developed for PsA, and the Group of Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) and Outcome Measures in Rheumatology (OMERACT) have been working on developing conclusive indices for PsA. (4) In our study, we aimed to evaluate patients with various disease activity using a variety of functional assessment indices.


Fifty patients (26 females, 24 males; mean age 46.02 [+ or -] 12.64 years; range 22 to 72) with PsA who were 18 years of age or older and were admitted to a physical medicine and rehabilitation follow-up outpatient clinic between October 2009 and September 2010 were included in this study. The diagnosis of PsA was made according to Classification Criteria for Psoriatic Arthitis (CASPAR). (5)

The patients' age, gender, duration of psoriasis, duration of PsA, nail involvement, and presence of dactylitis were noted, and their peripheral and axial joints were examined in detail. The patients with PsA were classified into five groups according to the Moll and Wright criteria. (2) In addition, any overlapping subgroups were also identified.

The Psoriasis Area and Severity Index (PASI) (6) scores of the patients were calculated by the same dermatologist. The Disease Activity Score including 28 joints (DAS28), (4) the Disease Activity Score for Reactive Arthritis (DAREA), (7) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (8) indices were used to assess the disease activity of the patients, and the Health Assessment Questionnaire (HAQ) (9) was applied for functional assessment. The results of the visual analog scale for pain (VAS-pain) (0-100 mm), patient global assessment (PaGA) and physician global assessment (PhGA) were also recorded. Furthermore, blood samples were obtained from the patients to determine the erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) levels.

Statistical analysis of the data was performed using the SPSS for Windows version 11.5 software program (SPSS Inc., Chicago, IL, USA), and normality of the continuous variables was analyzed using the Shapiro-Wilk test. The descriptive statistics were presented as mean [+ or -] standard deviation (SD) or median (interquartile range) for the continuous variables and as the number of the cases and percentage for the categorical variables. The significance of difference between the medians of the groups was investigated using the Mann-Whitney U test when there were two independent groups, and when there were more than two groups, the significance of difference was investigated using the Kruskal-Wallis test. In addition, the correlation of the continuous variables was investigated using Spearman's correlation test. A p value of < 0.05 was considered to be statistically significant.


The demographic characteristics of the patients are shown in Table 1. We found no significant differences related to gender and determined that the age at PsA onset of PsA was 35.8 [+ or -] 10.1 years (range 21-60).

Our findings also revealed that the asymmetrical oligoarticular type of PsA occurred most often (n = 28, 56%) while the distal interphalangeal (DIP) predominant type (n=2, 4%) and arthritis mutilans (n=2) were the least common. Some of the patients were included in more than one group

The onset times of psoriasis and arthritis were also determined. Simultaneous onset occurred if these two diseases started within the same one-year period. Arthritis started prior to the appearance of psoriatic lesions in four (8%) of the 50 patients, simultaneously with psoriasis in four others (8%), and after the psoriatic skin lesions in 42 patients (84%).

In addition, dactylitis was identified in eight patients (16%) and enthesis in 31 (62%) patients. Moreover, entheses was seen in 22 (95.7%) of the 23 patients with spondylitis and in nine (33.3%) of the 27 patients without spondylitis.

Furthermore, there was nail involvement in 38 patients (76%), and this was investigated in each clinical subgroup. Nail involvement occurred most often in those with the DIP predominant (100%) and arthritis mutilans (100%) subtypes of PsA while it was the least common in the symmetrical polyarthritis (50%) and spondylitis (62.5%) subtypes.

In this study, the mean PASI score was 5.22 [+ or -] 6.10 [median: 3.5 (range 0.8-37.7)]. When we grouped the PASI scores into mild, moderate, and severe categories, we found mild psoriasis in 70% (n = 35), moderate psoriasis in 26% (n =1 3), and severe psoriasis in 4% (n = 2) of the patients.

Laboratory investigations also revealed a mean ESR rate of 35.22 [+ or -] 23.57 mm/h (4.00-93.00) and a mean CRP level of 2.41 [+ or -] 3.97 mg/l (0.50-20). The patients were then grouped according to whether their ESR was > 20 mm/h or [less than or equal to] 20 mm/h and whether their CRP was > 1 or [greater than or equal to] 1, and we detected that the ESR was > 20 mm/h in 56% (n = 28) of the patients and the CRP level was > 1 mg/l in 40% (n = 20).

The results of the DAREA, DAS28, and BASDAI disease activity indices as well as the VA-Spain, PaGA, PhGA, and HAQ are summarized in Table 3.

We also investigated the relationship between the ESR and CRP values and the DAS28, DAREA, BASDAI, and PASI) and found that the DAS28 and DAREA scores had statistically significant correlations with both the ESR and CRP. In addition, the relationship between the BASDAI score and ESR (p < 0.05) was statistically significant, but there was no statistically significant relationship between the BASDAI and CRP (p > 0.05), despite there being a positive correlation. Furthermore, there was also no significant relationship between the PASI score and the ESR and CRP levels (Table 4).

When the relationship between the DAREA and the DAS28, HAQ, VAS-pain, PaGA, and PhGA was investigated, we found that it was strongest between the DAREA and DAS28 scores. The DAREA scores also had a statistically significant correlation with the VAS-pain, PaGA, and HAQ (p < 0.05), but the relationship with the PhGA did not reach statistical significance (Table 5).

Additionally, we assessed the relationship between the BASDAI scores and the PaGA, PhGA, and HAQ and found a significant correlation between the PaGA and PhGA in the spondylitis group (p < 0.025) (Table 6).


In our study, we determined that the mean age and duration of the arthritis symptoms of our patients were in agreement with other previously published studies. In addition, we found no significant differences according to gender, (10-12) and the most common type of PsA was the asymmetrical oligoarticular type, which also correlated with earlier research. (13-15)

The PASI was used to evaluate the extent and severity of the skin lesions, with erythema (redness), induration (thickness), and desquamation (scaling) of the lesions being assessed (6) Some studies have reported more severe skin lesions in patients with PsA15 while others have found no direct relationship between the severity and extensiveness of the skin lesions and arthritis symptoms. (16) Generally, most patients have mild/moderate skin lesions. However, Turkiewicz and Moreland (5) noted that skin and arthritis symptoms were simultaneously exacerbated in 30-40% of the patients with PsA, and Schoels et al. (17) reported a mean PASI score of 9.3 [+ or -] 10.1 In our study, the mean PASI score was lower at 5.22 [+ or -] 6.10 Similar to the literature, the majority of our patients had mild or moderate disease.

The DAS28 is a disease activity index that was developed for patients with RA. Since the joints used in the calculation of DAS28 do not include the foot and DIP joints, a number of investigators have advocated that its use with PsA should be limited. (5) Schoels et al. (17) reported a significant improvement in the DAS28 scores of patients with PsA after treatment with disease-modifying antirheumatic drugs (DMARDs) and biological therapy. In our study, because the DAS28 scores were significantly correlated with the ESR and CRP levels as well as the VAS-pain and HAQ, we concluded that it was a helpful adjunctive tool that could be used to follow up PsA activity.

Recently, the DAREA index, which has been in use since 2000 for reactive arthritis, has been utilized to assess joint activation. (7) Nell-Duxneuner et al. (18) investigated the suitability of disease activity indices in patients with PsA and identified three major headings which contained five different components: (i) patient-related data (PaGA and patient pain assessment), (ii) joint-related data (the number of tender and swollen joints), and (iii) acute phase reactants (CRP levels showed disease activity the best). These five components are reflected more thoroughly by the DAREA. (14) Schoels et al. (17) showed a significant correlation between the DAREA scores and the DAS28, VAS-pain, and HAQ scores along with the ESR and CRP levels, with significant improvement being seen in the DAREA scores in the treatment group. When the sensitivity of the alteration of the scores after the therapy was analyzed, no change was noted after 14 weeks in the placebo group, but there were variations in the other scores. This important finding indicates that the DAREA is a sensitive disease activity index for PsA. In addition, when radiological changes were evaluated at the end of [] week in the same study, a significant correlation was shown between the DAREA scores and these changes. Schoels et al. (17) reported that the DAREA was a suitable index for PsA and that it could be used under the heading of Disease Activity Index for Psoriatic Arthritis (DAPSA). In our study, we concluded that the DAREA was an easily calculated index that was beneficial for following up disease activity.

The BASDAI is an index that has been frequently used in the follow-up of the disease activity in patients with AS, and it has been reported that these scores are higher for patients with PsA who have axial involvement. (19) In our study, the BASDAI showed a significant correlation with ESR, an acute phase reactant, in both the axial and peripheral PsA groups. In addition, in the spondylitis group, we identified statistically significant relationships between the BASDAI and PaGA and PhGA.

The most characteristic laboratory test abnormalities are a high ESR and an increase in CRP levels in patients with PsA, with a rise in ESR occurring in 40% of those with this disease. Furthermore, the ESR is known to be the inflammatory marker that correlates best with the clinical joint score. (1) Gladman et al. (14) analyzed 220 patients with PsA and found an ESR of > 25 mm/h in 41% of the participants and reported that this was true for patients with both skin and joint disease activity. In addition, Moghaddassi et al. (12) reported an increased ESR in 79% of the patients and high CRP levels in 78.2%, and they believed that these findings were valuable prognostic signs. Gunal et al. (20) also evaluated 86 patients with PsA in Turkey and reported an ESR of > 30 mm/h in 40% of the study participants. In our study, we identified an ESR of 20 mm/h in 56% of the patients and a CRP level of 1 in 40%.


In this study, our findings indicated that DAS28 is a helpful adjunctive instrument to monitor PsA disease activity and that BASDAI may be more valuable in patients with spondylitis. In addition DAREA is found to be a valuable measurement to evaluate disease activity and functional status of patients with PsA reliably.

Declaration of conflicting interests

The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.


The authors received no financial support for the research and/or authorship of this article.

doi: 10.5606/tjr.2014.3400


(1.) Gladman DD, Clinical Features of Psoriatic Arthritis. In: Ricthlin CT, FitzGerald O, editors. 1st ed. Philedephia: Mosby, Inc affiliate of Elsevier Inc.; 2007. p. 11-19.

(2.) Moll JM, Wright V. Familial occurrence of psoriatic arthritis. Ann Rheum Dis 1973; 32:181-201.

(3.) Goupille P. Psoriatic arthritis. Joint Bone Spine 2005;72:466-70.

(4.) Bruce IN, Psoriatic arthritis: clinical features. In: Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors. 4th ed. Philedephia: Mosby, Inc affiliate of Elsevier Inc. 2008. p. 1165-77.

(5.) Turkiewicz AM, Moreland LW. Psoriatic arthritis: current concepts on pathogenesis-oriented therapeutic options. Arthritis Rheum 2007;56:1051-66.

(6.) Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978;157:238-44.

(7.) Eberl G, Studnicka-Benke A, Hitzelhammer H, Gschnait F, Smolen JS. Development of a disease activity index for the assessment of reactive arthritis (DAREA). Rheumatology (Oxford) 2000; 39:148-55.

(8.) Taylor WJ, Harrison AA. Could the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) be a valid measure of disease activity in patients with psoriatic arthritis? Arthritis Rheum 2004; 51:311-5.

(9.) Kucukdeveci AA, Sahin H, Ataman S, Griffiths B, Tennant A. Issues in cross-cultural validity: example from the adaptation, reliability, and validity testing of a Turkish version of the Stanford Health Assessment Questionnaire. Arthritis Rheum 2004; 51:14-9.

(10.) Ibrahim G, Waxman R, Helliwell PS. The prevalence of psoriatic arthritis in people with psoriasis. Arthritis Rheum 2009; 61:1373-8.

(11.) Green L, Meyers OL, Gordon W, Briggs B. Arthritis in psoriasis. Ann Rheum Dis 1981; 40:366-9.

(12.) Moghaddassi M, Shahram F, Chams-Davatchi C, Najafizadeh SR, Davatchi F. Different aspects of psoriasis: analysis of 150 Iranian patients. Arch Iran Med 2009; 12:279-83.

(13.) Kammer GM, Soter NA, Gibson DJ, Schur PH. Psoriatic arthritis: a clinical, immunologic and HLA study of 100 patients. Semin Arthritis Rheum 1979; 9:75-97.

(14.) Gladman DD, Shuckett R, Russell ML, Thorne JC, Schachter RK. Psoriatic arthritis (PSA)--an analysis of 220 patients. Q J Med 1987; 62:127-41.

(15.) Jamshidi F, Bouzari N, Seirafi H, Farnaghi F, Firooz A. The prevalence of PsA in Ps patients in Tehran, Iran. Arch Iranian Med 2008; 11:162-5.

(16.) Gladman DD. Psoriatic arthritis. Dermatologic Therapy 2004; 17:350-63.

(17.) Schoels M, Aletaha D, Funovits J, Kavanaugh A, Baker D, Smolen JS. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis 2010; 69:1441-7.

(18.) Nell-Duxneuner VP, Stamm TA, Machold KP, Pflugbeil S, Aletaha D, Smolen JS. Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis. Ann Rheum Dis 2010; 69:546-9.

(19.) Fernandez-Sueiro JL, Willisch A, Pertega-Diaz S, Tasende JA, Fernandez-Lopez C, Galdo F, et al. Evaluation of ankylosing spondylitis spinal mobility measurements in the assessment of spinal involvement in psoriatic arthritis. Arthritis Rheum 2009; 61:386-92.

(20.) Gunal EK, Kamali S, Gul A, Ocal L, Konice M, Aral O, et al. Clinical evaluation and comparison of different criteria for classification in Turkish patients with psoriatic arthritis. Rheumatol Int 2008; 28:959-64.

Fatma Gul YURDAKUL, [1] Filiz ESER, [1] Hatice BODUR, [1] Ulker GUL, [2] Muzeyyen GONUL, [2] I sil Deniz OGUZ [2]

[1] Department of Physical Medicine and Rehabilitation, Ankara Numune Training and Research Hospital, Ankara, Turkey

[2] Department of Dermatology, Ankara Numune Training and Research Hospital, Ankara, Turkey

Correspondence: Fatma Gul Yurdakul, M.D. Ankara Numune Egitim ve Arastirma Hastanesi Fizik Tedavi ve Rehabilitasyon Klinigi, 06100 Altindag, Ankara, Turkey.

Received: February 19, 2013 Accepted: June 06, 2013

Tel: +90 505-925 42 14 e-mail:

Presented at the 5th Turkish Rheumatology Congress, March 27-31,2012, Antalya, Turkey.
Table 1. Demographic characteristics of the patients with psoriatic

Variables          n    %     Mean [+ or -] SD    Median   Min.-Max.

Age                          46.0 [+ or -] 12.6
  Female           26   52
  Male             24   48
Age at the onset                                   35.8      21-60
  of PsA

SD: Standard deviation; Min.: Minimum; Max.: Maximum; PsA: Psoriatic

Table 2. Psoriatic arthritis patient distribution according to the
Moll and Wright criteria

                                              n     %
  Spondylitis                                 23   46
  DIP joint involvement                       2     4
  Asymmetrical oligoarthritis                 28   56
  Symmetrical polyarthritis                   8    16
  Arthritis mutilans                          2     4
Isolated and overlapped subtypes
  Isolated spondylitis                        10   20
  DIP joint involvement                       2     4
  Asymmetrical oligoarthritis                 15   30
  Symmetrical polyarthritis                   8    16
  Arthritis mutilans                          1     2
  Spondylitis + asymmetrical oligoarthritis   12   24
  Spondylitis + arthritis mutilans            1     2
  Asymmetrical oligoarthritis + arthritis
  mutilans                                    1     2
Total                                         50   100

DIP: Distal interphalangeal.

Table 3. The assessment parameters of the patients with psoriatic

Variables                         n    Mean [+ or -] SD

Disease activity score            50   10.1 [+ or -] 8.7
  for reactive arthritis
Psoriasis area and                50    5.2 [+ or -] 6.1
  severity index
Disease activity score            50    4.3 [+ or -] 1.2
  including 28 joints
Bath ankylosing spondylitis       50    3.8 [+ or -] 1.7
  disease activity index
Visual analog scale-pain          50   57.9 [+ or -] 24.6
Patient global assessment         50   52.3 [+ or -] 24.2
Physician global assessment       50   48.0 [+ or -] 19.6
Health assessment questionnaire   50    0.4 [+ or -] 0.5

Variables                         Median   Min.-Max.

Disease activity score             7.55    1.50-44.0
  for reactive arthritis
Psoriasis area and                 3.50    0.80-37.70
  severity index
Disease activity score             1.49    2.48-7.58
  including 28 joints
Bath ankylosing spondylitis        3.40    0.20-8.00
  disease activity index
Visual analog scale-pain          60.00    5.00-100.00
Patient global assessment         50.00    5.00-100.00
Physician global assessment       50.00    5.00-90.00
Health assessment questionnaire    0.25    0.00-2.85

SD: Standard deviation; Min.: Minimum; Max.: Maximum.

Table 4. The relationship between ESR and CRP and disease activity in
the patients with psoriatic arthritis


                                         r         p

Disease activity score including        0.520   <0.001
  28 joints
Psoriasis area and severity index      -0.045    0.756
Disease activity score for reactive     0.285    0.045 *
Bath ankylosing spondylitis disease     0.281    0.048 *
  activity index
ESR: Erythrocyte sedimentation rate;
CRP: C-reactive protein; * p < 0.05


                                          r        p        n

Disease activity score including        0.371   <0.001     50
  28 joints
Psoriasis area and severity index      -0.088    0.545     50
Disease activity score for reactive     0.386    0.006 *   50
Bath ankylosing spondylitis disease     0.248    0.083     50
  activity index
ESR: Erythrocyte sedimentation rate;
CRP: C-reactive protein; * p < 0.05

Table 5. The relationship between the disease
activity index for reactive arthritis and the
disease activity score 28, health assessment
questionnaire, visual analog scale-pain, patient
global assessment and physician global assessment
the in patients with psoriatic arthritis


                                R        p       n

Disease Activity Score        0.860    0.001 *   50
  including 28 joints
Visual analog scale-pain      0.379    0.007 *   50
Patient global assessment     0.316    0.025 *   50
Physician global assessment   0.272    0.084     50
Health assessment             0.312    0.028 *   50
DAREA: Disease activity index for reactive
arthritis; * p<0.05.

Table 6. The relationship between the bath ankylosing spondylitis
disease activity index and the patient global assessment, physician
global assessment and health assessment questionnaire in the patients
with and without spondylitis


                             With spondylitis Without spondylitis

                      R       p       n     r       p     n

Patient global      0.501   0.015 *   23   0.069   0.732   27
Physician global    0.479   0.021 *   23   0.065   0.748   27
Health assessment   0.382   0.071     23   0.276   0.178   27

BASDAI: Bath ankylosing spondylitis disease activity index; * p<0.025
COPYRIGHT 2014 Turkish League Against Rheumatism
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Yurdakul, Fatma Gul; Eser, Filiz; Bodur, Hatice; Gul, Ulker; Gonul, Muzeyyen; Oguz, Isil Deniz
Publication:Turkish Journal of Rheumatology
Date:Mar 1, 2014
Previous Article:Work absenteeism and its determinant factors in patients with Ankylosing Spondylitis: a cross-sectional study.
Next Article:Age, sex, and seasonal variations in the serum vitamin D3 levels in a local Turkish population.

Terms of use | Privacy policy | Copyright © 2022 Farlex, Inc. | Feedback | For webmasters |